References
- Alcock S. (1971). An anti-inflammatory compound: non-toxic to animals but with an adverse action in man. Proc Eur Soc Study Drug Toxic 12:184--90
- Boelsterli UA. (2002). Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 3:439–50
- Bradbury A, Powell GM, Curtis CG, Rhodes C. (1981). The enhanced biliary secretion of a taurine conjugate in the rat after intraduodenal administration of high doses of fenclozic acid. Xenobiotica 11:665–74
- Chalmers TM, Kellgren JH, Platt DS. (1969a). Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflamatory agent. II. Clinical trial in patients with rheumatoid arthritis. Ann Rheum Dis 28:595–601
- Chalmers TM, Pohl JE, Platt DS. (1969b). Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflammatory agent. I. Serum concentration studies in healthy individuals and in patients with rheumatoid arthritis. Ann Rheum Dis 28:590–4
- FDA. (2008). FDA Guidance for Industry: Safety Testing of Drug Metabolites. FDA Guidance on safety testing of drug metabolites. (2008). Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf [last accessed 2 Dec 2013]
- Foulkes DM. (1970). The metabolism of C14-ICI 54,450 (myalex) in various species – an in vivo NIH shift. J Pharmacol Exp Ther 172:115–21
- Hart FD, Bain LS, Huskisson EC, et al. (1970). Hepatic effects of fenzlozic acid. Ann Rheum Dis 29:684
- Knights KM, Sykes MJ, Miners JO. (2007). Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin Drug Metab Toxicol 3:159–68
- Le Y, Sauer B. (2001). Conditional gene knockout using Cre recombinase. Mol Biotechnol 17:269–75
- Newbould BB. (1969). The pharmacology of fenclozic acid (2-(4-chlorophenyl)-thiazol-4-ylacetic acid; I.C.I. 54,450; ‘Myalex’); a new compound with anti-inflammatory, analgesic and antipyretic activityl. Br J Pharmacol 35:487–97
- Pickup K, Gavin A, Jones HB, et al. (2012). The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: application to the metabolism of diclofenac. Xenobiotica 42:195–205
- Rodrigues AVM, Rollison HE, Martin S, et al. (2013). In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. Arch Toxicol 87:1569–79
- Skonberg C, Olsen J, Madsen KG, et al. (2008). Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol 4:425–38
- Stachulski AV, Harding JR, Lindon JC, et al. (2006). Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J Med Chem 49:6931–45
- Thompson RA, Isin EM, Li Y, et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Tox 25:1616–32
- Ullberg S. (1954). Studies on the distribution and fate of [35S]-labelled benzylpenicillin in the body. Acta Radiol Suppl 118:1–110